🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Global Health Concern

The sexually transmitted infection are increasing around the world, with figures suggesting in excess of 82 million infections each year. Particularly high rates are observed in the African continent and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the reality of growing infection rates, increasing antimicrobial resistance and the very limited available drugs at this time.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists believe that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This drug, which is also used to treat UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This approval represents a huge turning point in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

Based on data released by a prominent scientific publication, the new drug eradicated more than 90% of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which involves a dual-drug approach. The trial included over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Doctors treating patients have expressed positive views. The availability of a single-dose, oral treatment of this kind is described as a "critical tool" for managing the epidemic. This is deemed vital to alleviate the strain of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.